- Home
- Our company
- Office of the Chief Medical Officer
Office of the Chief Medical Officer
The Johnson & Johnson Office of the Chief Medical Officer (OCMO) champions healthcare innovation that patients can trust. We believe health is everything, uniquely combining safety science, epidemiology bioethics and lifecycle management expertise to inform evidence- and science-based product decisions that put patients first. We lead with care and rigorous science to build a world where patients are as safe as possible and people-centered innovation is paramount.
Johnson & Johnson Chief
Medical Officers
Our senior leadership team drives medical safety excellence and innovation across Johnson & Johnson.
-
Penny Heaton, M.D., is the Global Head of the Johnson & Johnson Office of the Chief Medical Officer which, aligned with Our Credo, keeps patients at the center of the company’s efforts to tackle the world’s toughest health challenges through its leadership in Medical Safety, Epidemiology, Bioethics and product Lifecycle Management. -
Jijo is the Chief Medical Officer for Johnson & Johnson MedTech & Interventional Oncology. In this role, he drives strong safety governance and risk management across the product lifecycle, promoting safe and effective patient outcomes. Jijo is a member of the Office of the Chief Medical Officer Senior Leadership Team and the Johnson & Johnson Interventional Oncology Senior Leadership Team. Previously, Jijo was the Chief Medical Officer for the Johnson & Johnson Family of Consumer Companies, now known as Kenvue, where he led the Safety Council for the Consumer sector and was a member of the Consumer R&D Leadership Team. From 2021-2023 he served as the Chair of the Board of Directors of the Medical Device Innovation Consortium (MDIC) and continues to serve as an active member on the organization’s board of directors.
Delivering medical safety excellence that puts people first
Safety is embedded in our culture and aligned with Our Credo. We enable proactive medical safety excellence across the product lifecycle, so our medicines and devices are safe and effective for patients.
Safety science innovation: Putting patients first
Steve Lin and Richard Mayer, leaders in Johnson & Johnson’s Office of the Chief Medical Officer, share insights into the company’s patient-centered approach.
Decisions through real-world evidence
We are leading the way in generating regulatory-grade real-world evidence (RWE) to further our understanding of the safety and effectiveness of our products and inform more timely product decisions.
What is real-world evidence and how does it help patients?
As Johnson & Johnson’s Vice President and Global Head of Epidemiology, Josh Gagne and his team study real-world data to further understand the safety and effectiveness of our products across many different kinds of patients and clinical environments to help inform important decisions that ultimately improve care for patients
Ethical scientific practices & policies
We provide bioethical guidance to teams across our enterprise to help drive innovation that is respectful to the rights and welfare of all people.
How Johnson & Johnson is helping patients through its compassionate use program
The company’s mission is to care for the world—one person at a time. Learn how Johnson & Johnson is leading the charge to improve the process by which very sick patients may apply for access to investigational medications.